Endocrinology, Vol 137, 4130-4138, Copyright © 1996 by Endocrine Society

ARTICLES

Glucagon-like peptide-1 (GLP-1) releases thyrotropin (TSH): characterization of binding sites for GLP-1 on alpha-TSH cells

SA Beak, CJ Small, I Ilovaiskaia, JD Hurley, MA Ghatei, SR Bloom and DM Smith
Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.

We have demonstrated specific binding sites for [125I]glucagon-like peptide 1 (GLP-1) on membranes from the rodent thyrotrope cell line, alpha-TSH. Specific [125I]GLP-1 binding was saturable and time dependent. Equilibrium saturation binding analysis was consistent with the presence of a single class of binding site (binding capacity, 85 +/- 7 fmol/mg protein) with a dissociation constant (Kd) of 28 +/- 13 pM. The specific GLP-1 receptor agonists, exendin-4 and exendin-3, and the antagonist, exendin-(9-39), bound to the receptor sites with high affinity (Ki = 190 +/- 70 pM; 130 +/- 50 and 1200 +/- 470 pM, respectively). Chemical cross-linking of [125I]GLP-1-receptor complexes revealed a single band of 64,300 +/- 100 Mr in alpha-TSH membranes. In addition, specific PCR studies demonstrated the presence of GLP-1 receptor messenger RNA. Binding of the peptide to alpha-TSH cell membranes resulted in increased intracellular cAMP concentrations (10 nM GLP-1, 1010 +/- 83 pmol/10(6) cells.h; control, 175 +/- 60 pmol/10(6) cells.h; P < 0.002), indicating that the receptor is linked to stimulation of adenylyl cyclase. GLP-1-mediated increases in cAMP were inhibited by exendin-(9-39) in a dose-dependent manner. Furthermore, GLP-1 stimulates basal TSH release from dispersed anterior pituitary cells in a concentration-dependent manner (100 nM GLP-1, 63 +/- 3 fmol/10(6) cells.h; control, 35 +/- 1 fmol/10(6) cells.h; P < 0.0005), but had no effect on basal PRL, GH, or LH release.

This article has been cited by other articles:

				M. Korner, M. Stockli, B. Waser, and J. C. Reubi GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting J. Nucl. Med., May 1, 2007; 48(5): 736 - 743. [Abstract] [Full Text] [PDF]

				K. B. Degn, B. Brock, C. B. Juhl, C. B. Djurhuus, J. Grubert, D. Kim, J. Han, K. Taylor, M. Fineman, and O. Schmitz Effect of Intravenous Infusion of Exenatide (Synthetic Exendin-4) on Glucose-Dependent Insulin Secretion and Counterregulation During Hypoglycemia Diabetes, September 1, 2004; 53(9): 2397 - 2403. [Abstract] [Full Text] [PDF]

				G. Kuriyama, S. Takekoshi, K. Tojo, Y. Nakai, M. J. Kuhar, and R. Y. Osamura Cocaine- and Amphetamine-Regulated Transcript Peptide in the Rat Anterior Pituitary Gland Is Localized in Gonadotrophs and Suppresses Prolactin Secretion Endocrinology, May 1, 2004; 145(5): 2542 - 2550. [Abstract] [Full Text] [PDF]

				K. E. Mayo, L. J. Miller, D. Bataille, S. Dalle, B. Goke, B. Thorens, and D. J. Drucker International Union of Pharmacology. XXXV. The Glucagon Receptor Family Pharmacol. Rev., March 1, 2003; 55(1): 167 - 194. [Abstract] [Full Text] [PDF]

				C. L. Dakin, C. J. Small, A. J. Park, A. Seth, M. A. Ghatei, and S. R. Bloom Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats Am J Physiol Endocrinol Metab, December 1, 2002; 283(6): E1173 - E1177. [Abstract] [Full Text] [PDF]

				M. A. Nauck, M. M. Heimesaat, K. Behle, J. J. Holst, M. S. Nauck, R. Ritzel, M. Hufner, and W. H. Schmiegel Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy Volunteers J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1239 - 1246. [Abstract] [Full Text] [PDF]

				C. L. Dakin, I. Gunn, C. J. Small, C. M. B. Edwards, D. L. Hay, D. M. Smith, M. A. Ghatei, and S. R. Bloom Oxyntomodulin Inhibits Food Intake in the Rat Endocrinology, October 1, 2001; 142(10): 4244 - 4250. [Abstract] [Full Text] [PDF]

				H. L. Ward, C. J. Small, K. G. Murphy, A. R. Kennedy, M. A. Ghatei, and S. R. Bloom The Actions of Tuberoinfundibular Peptide on the Hypothalamo-Pituitary Axes Endocrinology, August 1, 2001; 142(8): 3451 - 3456. [Abstract] [Full Text] [PDF]

				D. J. Drucker Minireview: The Glucagon-Like Peptides Endocrinology, February 1, 2001; 142(2): 521 - 527. [Abstract] [Full Text] [PDF]

				F. Satoh, S. A. Beak, C. J. Small, M. Falzon, M. A. Ghatei, S. R. Bloom, and D. M. Smith Characterization of Human and Rat Glucagon-Like Peptide-1 Receptors in the Neurointermediate Lobe: Lack of Coupling to Either Stimulation or Inhibition of Adenylyl Cyclase Endocrinology, April 1, 2000; 141(4): 1301 - 1309. [Abstract] [Full Text] [PDF]

				R. J. Seeley, S. C. Woods, and D. D'Alessio Editorial: Targeted Gene Disruption in Endocrine Research--The Case of Glucagon-Like Peptide-1 and Neuroendocrine Function Endocrinology, February 1, 2000; 141(2): 473 - 475. [Full Text] [PDF]

				N. J. MacLusky, S. Cook, L. Scrocchi, J. Shin, J. Kim, F. Vaccarino, S. L. Asa, and D. J. Drucker Neuroendocrine Function and Response to Stress in Mice with Complete Disruption of Glucagon-Like Peptide-1 Receptor Signaling Endocrinology, February 1, 2000; 141(2): 752 - 762. [Abstract] [Full Text] [PDF]

				T. J. Kieffer and J. Francis Habener The Glucagon-Like Peptides Endocr. Rev., December 1, 1999; 20(6): 876 - 913. [Abstract] [Full Text]

				H. Yang, J. M. Egan, Y. Wang, C. D. Moyes, J. Roth, M. H. Montrose, and C. Montrose-Rafizadeh GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor Am J Physiol Cell Physiol, September 1, 1998; 275(3): C675 - C683. [Abstract] [Full Text] [PDF]

				A. S. Ryan, J. M. Egan, J. F. Habener, and D. Elahi Insulinotropic Hormone Glucagon-Like Peptide-1-(7-37) Appears Not to Augment Insulin-Mediated Glucose Uptake in Young Men during Euglycemia J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2399 - 2404. [Abstract] [Full Text]

				J. Lovshin, J. Estall, B. Yusta, T. J. Brown, and D. J. Drucker Glucagon-like Peptide (GLP)-2 Action in the Murine Central Nervous System Is Enhanced by Elimination of GLP-1 Receptor Signaling J. Biol. Chem., June 8, 2001; 276(24): 21489 - 21499. [Abstract] [Full Text] [PDF]